Volitionrx Limited

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

VolitionRx reports 240% revenue growth, eyes expansion in veterinary diagnostics

VolitionRx reported strong revenue growth in 2022 but faced a net loss due to higher costs, emphasizing the need for cost management.
The company's focus on commercializing its Nu.Q platform and expanding into veterinary diagnostics presents growth opportunities.
While challenges like increased expenditures and competition exist, VolitionRx's strategic partnerships and product pipeline position it for future success.
Exploring new applications of NETosis technology in animal health and upcoming investor events highlight potential growth avenues for VolitionRx.

VolitionRx reports robust Q1 results, eyes growth in cancer testing

VolitionRx Limited's Q1 2023 performance reflects strong financials, strategic partnerships, and promising revenue from innovative cancer testing products.
The company's strengths include financial stability, strategic collaborations, and growth potential in the veterinary and cancer testing markets.
Challenges in managing expenses, sustaining revenue growth, and strategic focus require careful navigation for continued success.
Opportunities abound in leveraging partnerships, exploring new markets, and proactive initiatives for future growth and market expansion.

VolitionRx reports robust Q2 earnings, poised for growth in cancer diagnostics

VolitionRx Limited delivered a strong performance in Q2 2023, marked by significant revenue growth and a solid financial position, underpinned by cash reserves and milestone payments.
The company's focus on advancing Nu.Q technology, expanding partnerships, and making progress in cancer research bodes well for future growth and innovation.
While facing challenges in scaling sales efforts and managing R&D expenses, VolitionRx has opportunities to drive revenue growth through strategic partnerships and market expansion.

VolitionRx reports robust revenue growth and global expansion opportunities

VolitionRx Limited's Q3 2023 performance showcased strong revenue growth and global expansion in Nu.Q Vet Cancer Test sales.
While facing challenges in regulatory timelines and funding, the company's strategic strengths lie in its innovative products and prudent financial approach.
Opportunities in new product launches, market education, and global expansion position VolitionRx for continued growth and breakthroughs in cancer detection.

VolitionRx reports stellar revenue growth, eyes global expansion with strategic partnerships

VolitionRx Limited's Q4 2023 earnings call highlighted robust revenue growth, strong cash position, and strategic partnerships driving expansion. While facing challenges in financing and operational efficiency, the company's focus on innovative technologies and global market penetration positions it well for future growth and partnerships.

Volitionrx reports revenue growth and eyes cash flow positivity by 2025

Volitionrx Limited (VNRX) is on track for growth with strong revenue performance, successful product launches, and a focus on achieving cash flow positivity. The company faces challenges in expense control and funding strategies but has opportunities in upcoming data releases and licensing deals.

Volitionrx reports robust Q3 revenue growth and strategic advancements

Volitionrx Limited demonstrated strong performance in revenue growth, innovation, and financial progress.
Key strengths include successful product sales, research advancements, and strategic financial planning.
Challenges in market dynamics and cost management require strategic focus and operational efficiency improvements.
Opportunities for growth exist in market expansion, cost optimization, new partnerships, and research publications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

HENDERSON, Nev. , Jan. 20, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, which will focus on Volition's Nu.Q® Vet commercial strategy.

Volition to Take Part in Nu.Q® Vet Commercial Strategy Webinar

IDEXX Laboratories

VolitionRx Ltd (NYSE-A:VNRX) has announced the availability of its Nu.Q Vet Cancer Test through the IDEXX Laboratories Inc reference laboratory network in the US. The Henderson, Nevada-based multi-national epigenetics company noted that IDEXX is a global leader in pet healthcare innovation and is well-positioned to roll out the IDEXX Nu.Q Canine Cancer Screen worldwide.

VolitionRx announces expansion of availability of Nu.Q Vet Cancer Test availability through IDEXX's reference laboratory network

HENDERSON, Nev. , Jan. 12, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the availability of its Nu.Q® Vet Cancer Test through the IDEXX Laboratories, Inc. ("IDEXX") reference laboratory network in the U.S.   Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said: "IDEXX is a global leader in pet healthcare innovation and well-positioned to roll out the IDEXX Nu.Q® Canine Cancer Screen worldwide.

Volition Announces Expansion of Availability of the Nu.Q® Vet Cancer Test Through IDEXX's Reference Laboratory Network

VolitionRx (NYSE-A:VNRX) has outlined its key achievements in 2022 as the organization transitions from a company solely focused on research and development to one with commercial operations. Henderson, Nevada-based Volition is a multi-national epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19.

VolitionRx highlights 2022 achievements as it advances to commercial operations

HENDERSON, Nev , Jan. 8, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2022, outlining its key highlights as the organization transitions from a company solely focused on research and development to one with commercial operations. Volition's major achievements in 2022 include: Expanding access to the Nu.Q® Vet Cancer Test on a worldwide basis Achieving a CE mark for Nu.Q® NETs Launching its U.S. clinical product development and regulatory programs Developing its Nu.Q® pipeline    Scaling up its operations     Read Volition's Business Review here or watch the video below.

Volition Issues Business Review 2022

Akebia Therapeutics

Astra Space

SoFi Technologies

Exicure Inc

X4 Pharmaceuticals Inc

Insiders are buying these penny stocks but are they worth the risk? The post Penny Stocks To Buy: 6 Insider Picks Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy: 6 Insider Picks Before 2023

Insiders are buying these penny stocks but are they worth the risk? The post 3 Top Penny Stocks To Buy According To Insiders Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Top Penny Stocks To Buy According To Insiders Before 2023

VolitionRx Limited (NYSE:VNRX ) Q3 2022 Earnings Conference Call November 15, 2022 8:30 AM ET Company Participants Scott Powell - IR Cameron Reynolds - Founder, Group CEO Tom Butera - CEO, Volition Veterinary Terig Hughes - CFO Conference Call Participants Michael Okunewitch - Maxim Group Bruce Jackson - The Benchmark Company Steven Ralston - Zacks Operator Good morning, ladies and gentlemen. Thank you for standing by.

VolitionRx Limited (VNRX) Q3 2022 Earnings Call Transcript

VolitionRx (NYSE-A:VNRX) said it ended third-quarter 2022 with US$16.4 million in cash and cash equivalents, thanks to careful management of expenditures with net cash used in operating activities averaging approximately $2.3 million per month in the quarter. Cash equivalents was down slightly from $16.7 million at the quarter ended June 30, 2022, the Henderson, Nevada-based company said.

VolitionRX ends Q3 with $16.4 million cash, moves from R&D to commercial cancer screening company

Conference call to discuss financial and operational results scheduled for Tuesday, November 15, at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.

VolitionRx Limited Announces Third Quarter 2022 Financial Results and Business Update

VolitionRx (NYSE-A:VNRX) Limited said it will work with a renowned French veterinary referral clinic to further assess the potential of its cancer screening technology in dogs and cats. A non-interventional study of Volition's Nu.Q Vet Cancer Test will be overseen by Dr Jérôme Benoit, the clinical director of Oncovet in Lille.

VolitionRx teams up with leading French veterinary group to assess potential of cancer screening technology

HENDERSON, Nev. , Nov. 14, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced a clinical research study with Oncovet, a renowned veterinary referral clinic, specializing in medical and radiation oncology.

Volition Announces Clinical Research Study with Oncovet

HENDERSON, Nev. , Nov. 10, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has been invited to participate in a government-backed prospective study to evaluate the performance of blood biomarkers in the early detection of lung cancer with Hospices Civils de Lyon ("HCL"), France's second largest university hospital.

Volition to Participate in a Lung Cancer Screening Study in France

VolitionRx (NYSE-A:VNRX) said it has launched its Nu.Q cancer-screening test for use by veterinarians across the US and anticipates the upcoming launch in Europe by the Heska Corporation through that company's veterinary diagnostic laboratories. Henderson, Nevada-based VolitionRx (NYSE-A:VNRX) said it has worked closely with Heska over the past six months.

VolitionRX launches Nu.Q cancer-screen test for dogs in US, preps for European launch by Heska

Heska

HENDERSON, Nev. , Nov. 3, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its Nu.Q® Vet Cancer Screening Test across the U.S. and the forthcoming launch in Europe by Heska Corporation (NASDAQ: HSKA) ("Heska"), a leading global provider of advanced veterinary diagnostics, through Heska's veterinary diagnostic laboratories.

Volition Announces the Launch of the Nu.Q® Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories

VolitionRx (NYSE-A:VNRX) said it has signed a global agreement with a market leader in pet healthcare to supply its Nu.Q Vet Cancer Test to veterinarians. According to VolitionRx (NYSE-A:VNRX), there are approximately 84 million pet dogs in the US.

VolitionRX inks global agreement to provide Nu.Q cancer detection test to veterinarians

HENDERSON, Nev. , Oct. 20, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the signing of a global supply agreement with a market leader in pet healthcare (the "Company").

Volition Signs Global Supply Agreement for Nu.Q® Vet Cancer Test

Xenetic Biosciences

Signing of patent assignment from CLS Therapeutics as part of a collaboration agreement with Volition and CLS Therapeutics to develop NETs-targeted adoptive cell therapies for the treatment of cancer FRAMINGHAM, MA / ACCESSWIRE / October 11, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced the signing of a patent assignment from CLS Therapeutics, Inc. ("CLS") to Xenetic related to Xenetic's previously announced collaboration with VolitionRx Limited (NYSE AMERICAN:VNRX) ("Volition"), a multi-national epigenetics company, and CLS, a biopharmaceutical company developing first-in-class therapies based on the discovery of novel therapeutic targets. In consideration of the patent assignment, Xenetic will also issue 850,000 shares of common stock to CLS.

Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics

VolitionRx (NYSE-A:VNRX) Limited said it has appointed veteran marketing executive Mickie Henshall to its board of directors. The company noted that Henshall has over 20 years of experience in developing and implementing marketing and sales strategies within the IVD, clinical, and life science industries.

VolitionRx adds marketing executive Mickie Henshall to its board of directors

HENDERSON, Nev. , Aug. 16, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE: VNRX) ("Volition"), a multi-national epigenetics company, has announced the appointment of Mickie Henshall to its board of directors effective August 15, 2022.

Volition Appoints Mickie Henshall as an Independent Director

VolitionRx Limited (NYSE:VNRX ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Scott Powell - IR Cameron Reynolds - CEO Dr. Tom Butera - CEO, Volition Veterinary Terig Hughes - CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Bruce Jackson - The Benchmark Company Nathan Weinstein - Aegis Capital Steven Ralston - Zacks Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to VolitionRx Limited's Second Quarter '22 Earnings Conference Call.

VolitionRx Limited (VNRX) CEO Cameron Reynolds on Q2 2022 Results - Earnings Call Transcript

VolitionRx (NYSE-A:VNRX) Limited ended the second quarter with $16.7 million in the bank to help advance research and commercialization efforts for its Nucleosomics platform for blood tests. The Henderson, Nevada-based epigenetics company had a busy quarter that saw it receive a CE Mark for its Nu.Q Netosis (NETs) test in Europe and reveal new clinical studies for NETs in the US.

VolitionRx ends 2Q with $16.7M, secures further funding to advance trials and commercialization efforts

Conference call to discuss financial and operational results scheduled for Thursday, August 11, at 8:30 a.m. U.S. Eastern Time HENDERSON, Nevada , Aug. 10, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the second quarter ended June 30, 2022.

VolitionRx Limited Announces Second Quarter 2022 Financial Results and Business Update

VolitionRx (NYSE-A:VNRX) Limited has announced a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of neutrophil extracellular traps (NETs) in cancer patients with sepsis.  The diagnostics and monitoring company said the trial will use Volition's Nu.Q NETs test for the study, which was Conformitè Europëenne (CE) marked earlier this year for the detection and evaluation of NETosis.

VolitionRx to participate in US clinical study for NETs in sepsis cancer patients

HENDERSON, Nev. , Aug. 10, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of neutrophil extracellular traps ("NETs") in cancer patients with sepsis.

News for Volitionrx Limited Stock (VNRX)